Eli Lilly and Company, a multinational pharmaceutical company, has reached a significant milestone, becoming the first health-care company in the world to achieve a $1 trillion market capitalization as of November 15, 2025. Headquartered in Indianapolis, Indiana, the company has a global presence with offices in 18 countries and its products being sold in approximately 125 countries. The company’s history dates back to 1876 when it was founded by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War.
Over the years, Eli Lilly and Company has grown to become one of the largest biomedical companies in the world, ranked 4th by revenue. It is also the most valuable pharmaceutical company worldwide, ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000.
Eli Lilly and Company has a diverse portfolio of products, with its primary offerings including tirzepatide (Mounjaro and Zepbound) for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea. This product accounted for 37% of the company’s revenues in 2024. Another key product is abemaciclib (Verzenio) for the treatment of advanced or metastatic breast cancers, which accounted for 12% of 2024 revenues.
The company also offers dulaglutide (Trulicity) for the treatment of type 2 diabetes, which accounted for 12% of 2024 revenues. In addition to these products, Eli Lilly and Company also offers ixekizumab (Taltz) for the treatment of autoimmune diseases, which accounted for 7% of 2024 revenues.
The company’s product portfolio is a testament to its commitment to developing innovative treatments for various diseases and conditions. With a strong presence in the global pharmaceutical market, Eli Lilly and Company continues to be a major player in the industry. The company’s achievement of a $1 trillion market capitalization is a significant milestone, reflecting its strong financial performance and growth prospects.
As a leader in the pharmaceutical industry, Eli Lilly and Company is well-positioned to continue developing new treatments and expanding its product portfolio. With its global presence and commitment to innovation, the company is likely to remain a major player in the industry for years to come. Looking ahead, it will be interesting to see how Eli Lilly and Company continues to grow and evolve in the coming years.
With its strong product portfolio and commitment to innovation, the company is well-positioned to address the evolving needs of the healthcare industry. As the pharmaceutical industry continues to evolve, Eli Lilly and Company is likely to remain a key player, driving innovation and growth in the years to come.
As of now, the company’s future prospects look promising, and it will be worth watching how it continues to develop and expand its product portfolio to address the changing needs of the healthcare industry.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Eli Lilly and Company”, “description”: “Eli Lilly and Company, a multinational pharmaceutical company, has reached a significant milestone, becoming the first health-care company in the world to achieve a $1…”, “datePublished”: “2025-11-15T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Noah King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “image”: “https://upload.wikimedia.org/wikipedia/commons/a/af/American_Pharma_Major_Eli_Lilly_Opens_its_Tech_%26_Innovation_Centre_in_Hyderabad_%2823040%29.jpg?utm_source=commons.wikimedia.org&utm_campaign=imageinfo&utm_content=original”}
